<DOC>
	<DOCNO>NCT03081351</DOCNO>
	<brief_summary>This clinical trial survival benefit extend lymphadenectomy nerve clearance versus standard lymphadenectomy pancreaticoduodenectomy pancreatic adenocarcinoma，which multicenter，prospective，ramdomized clinical trial .</brief_summary>
	<brief_title>Extended Retroperitoneal Lymphadenectomy Nerve Plexus Clearance Versus Standard Lymphadenectomy Pancreaticoduodenectomy</brief_title>
	<detailed_description>The purpose clinical trial assess survival benefit extend lymphadenectomy nerve clearance versus standard lymphadenectomy pancreaticoduodenectomy pancreatic adenocarcinoma . And focus R0 resection use LEEPP ( Leeds Pathology Protocol ) method check whether tumor eradicate .</detailed_description>
	<criteria>1870 year ; Karnofsky performance &gt; 70 ; preoperative diagnosis resectable pancreatic head cancer ; patient ' relative sign consent form . also severe cardiopulmonary disease , autoimmune disease , chronic renal failure disease ; recurrent pancreatic tumor unresectable tumor ; benign pancreatic tumor ; also malignant tumor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Extended retroperitoneal lymphadenectomy , Nerve plexus clearance , Survival benefit</keyword>
</DOC>